Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover extension of iptacopan for adults with primary IgA nephropathy after parent Novartis studies
CTR20222718Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in IgA nephropathy (IgAN), sponsored by Novartis. Started Mar 2023; status: active.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20222718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222718.